We are proud to announce that PhenoPath is now part of AmeriPath.
* Panel makeup subject to change
Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) has several recurrent and prognostic genetic alterations that have been characterized and are useful in the management of patients. Loss of 13q14.3 is the most common molecular alteration in CLL/SLL (~36% of all CLL/SLL cases) and as a sole abnormality often portends a favorable clinical course. Loss of 17p13.1(P53) or 11q22.3(ATM) are less common and are adverse prognostic markers in CLL/SLL. Trisomy 12, as detected by CEP12 FISH is a marker of intermediate prognosis. This panel includes IGH and t(11;14) FISH probes to aid in the differentiation of CLL/SLL cases from mantle cell lymphoma.
CPT Code(s): 88374x5, 88367 (reference only; CPTs may vary)
Turnaround Time: Within 3-4 business days of receipt
Schedule: Monday - Friday
• Peripheral blood, Preferred: 3 ml in sodium heparin (green top) / Acceptable: 3 ml in EDTA (purple top) - OR -
• Bone marrow aspirate, Preferred: 1-2 ml in sodium heparin (green top) / Acceptable: 1-2 ml in EDTA (purple top) - OR -
• Fresh tissue in RPMI